JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

21.52 4.31

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.62

Максимум

21.53

Ключови измерители
By Trading Economics
Приходи	-7.3M -68M
Продажби	23M 68M
Марж на печалбата	-99.318
Служители	298
EBITDA	42M -15M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+91.76% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	123M 1.9B
Предишно отваряне	17.21
Предишно затваряне	21.52

Настроения в новините

By Acuity

100%

335 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.04.2026 г., 23:08 ч. UTC

Печалби

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30.04.2026 г., 23:07 ч. UTC

Печалби

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30.04.2026 г., 22:20 ч. UTC

Печалби

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30.04.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise After Gains on Wall Street -- Market Talk

30.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30.04.2026 г., 23:27 ч. UTC

Пазарно говорене

Liontown Lithium Recovery Expected to Improve -- Market Talk

30.04.2026 г., 23:22 ч. UTC

Печалби

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30.04.2026 г., 23:20 ч. UTC

Пазарно говорене

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30.04.2026 г., 22:52 ч. UTC

Печалби

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30.04.2026 г., 22:33 ч. UTC

Печалби

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30.04.2026 г., 22:32 ч. UTC

Печалби

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30.04.2026 г., 22:32 ч. UTC

Печалби

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30.04.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30.04.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30.04.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30.04.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30.04.2026 г., 22:11 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.04.2026 г., 22:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.04.2026 г., 22:11 ч. UTC

Пазарно говорене

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30.04.2026 г., 22:05 ч. UTC

Печалби

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30.04.2026 г., 21:57 ч. UTC

Печалби

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30.04.2026 г., 21:56 ч. UTC

Печалби

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30.04.2026 г., 21:56 ч. UTC

Печалби

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30.04.2026 г., 21:55 ч. UTC

Печалби

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30.04.2026 г., 21:54 ч. UTC

Печалби

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30.04.2026 г., 21:54 ч. UTC

Печалби

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30.04.2026 г., 21:53 ч. UTC

Печалби

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30.04.2026 г., 21:49 ч. UTC

Печалби

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30.04.2026 г., 21:49 ч. UTC

Печалби

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

91.76% нагоре

12-месечна прогноза

Среден 39.56 USD 91.76%

Висок 57 USD

Нисък 28 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

335 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.